Tdspharm Co., Ltd. (KOSDAQ:464280)

Tdspharm Statistics

Total Valuation

Tdspharm has a market cap or net worth of KRW 56.46 billion. The enterprise value is 34.41 billion.

Market Cap	56.46B
Enterprise Value	34.41B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Tdspharm has 5.53 million shares outstanding. The number of shares has increased by 20.86% in one year.

Current Share Class	5.53M
Shares Outstanding	5.53M
Shares Change (YoY)	+20.86%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	91.96%
Owned by Institutions (%)	4.27%
Float	419,326

Valuation Ratios

The trailing PE ratio is 19.69.

PE Ratio	19.69
Forward PE	n/a
PS Ratio	2.46
PB Ratio	1.42
P/TBV Ratio	1.43
P/FCF Ratio	109.52
P/OCF Ratio	32.95
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.68, with an EV/FCF ratio of 66.75.

EV / Earnings	12.90
EV / Sales	1.50
EV / EBITDA	14.68
EV / EBIT	20.78
EV / FCF	66.75

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.17.

Current Ratio	3.70
Quick Ratio	3.38
Debt / Equity	0.17
Debt / EBITDA	2.96
Debt / FCF	13.45
Interest Coverage	6.82

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	4.15%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Tdspharm has paid 192.06 million in taxes.

Income Tax	192.06M
Effective Tax Rate	6.72%

Stock Price Statistics

The stock price has decreased by -68.19% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-68.19%
50-Day Moving Average	10,689.80
200-Day Moving Average	12,403.40
Relative Strength Index (RSI)	41.32
Average Volume (20 Days)	20,414

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tdspharm had revenue of KRW 22.94 billion and earned 2.67 billion in profits. Earnings per share was 518.65.

Revenue	22.94B
Gross Profit	5.79B
Operating Income	1.66B
Pretax Income	2.86B
Net Income	2.67B
EBITDA	2.34B
EBIT	1.66B
Earnings Per Share (EPS)	518.65

Balance Sheet

The company has 28.98 billion in cash and 6.93 billion in debt, giving a net cash position of 22.05 billion or 3,987.06 per share.

Cash & Cash Equivalents	28.98B
Total Debt	6.93B
Net Cash	22.05B
Net Cash Per Share	3,987.06
Equity (Book Value)	39.73B
Book Value Per Share	7,512.45
Working Capital	27.36B

Cash Flow

In the last 12 months, operating cash flow was 1.71 billion and capital expenditures -1.20 billion, giving a free cash flow of 515.56 million.

Operating Cash Flow	1.71B
Capital Expenditures	-1.20B
Free Cash Flow	515.56M
FCF Per Share	93.23

Margins

Gross margin is 25.23%, with operating and profit margins of 7.22% and 11.63%.

Gross Margin	25.23%
Operating Margin	7.22%
Pretax Margin	12.46%
Profit Margin	11.63%
EBITDA Margin	10.22%
EBIT Margin	7.22%
FCF Margin	2.25%

Dividends & Yields

Tdspharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.86%
Shareholder Yield	n/a
Earnings Yield	4.73%
FCF Yield	0.91%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Tdspharm has an Altman Z-Score of 7.26 and a Piotroski F-Score of 3.

Altman Z-Score	7.26
Piotroski F-Score	3